Harvest Volumes of Salmon and Trout - Total harvest volume of salmon and trout for Q4 2025 was 49,300 GWT, a decrease from 56,800 GWT in Q4 2024 [1] - For the full year 2025, harvested volume of salmon and trout was 195,600 GWT, an increase from 171,200 GWT in 2024 [1] - Harvest volumes by region/company for Q4 2025 included Lerøy Aurora at 16.4 GWT (up from 15.4 GWT), Lerøy Midt at 16.2 GWT (down from 22.6 GWT), and Lerøy Sjøtroll at 16.8 GWT (down from 18.8 GWT) [1] Catch Volumes of Wildfish - Total wild catch volumes in Lerøy Havfisk for Q4 2025 were 7.6 thousand tonnes, down from 9.8 thousand tonnes in Q4 2024 [2] - The catch volume for 2025 was 57,700 tonnes, a decrease from 65,000 tonnes in 2024 [2] Upcoming Report - The complete Q4 2025 report will be released on 24 February at 06:30 CET [3]

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 2,212,000 shares of common stock priced at $260.00 per share, aiming to raise approximately $575 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering consists of 2,212,000 shares at a price of $260.00 per share, with expected gross proceeds of around $575 million [1]. - Praxis has granted underwriters a 30-day option to purchase up to 331,800 additional shares at the same public offering price [1]. - The offering is anticipated to close on or about January 8, 2026, subject to market conditions and customary closing conditions [1]. Group 2: Underwriters - Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2]. - LifeSci Capital, Baird, and Oppenheimer & Co. are serving as lead managers, while H.C. Wainwright & Co. and Needham & Company are co-managers [2]. Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3]. - A preliminary prospectus supplement was filed with the SEC on January 6, 2026, and the final prospectus will also be filed with the SEC [3].

Core Insights - BLUETTI has launched two new products in Canada: the Elite 400 Portable Power Station and the Charger 2 Unified Alternator & Solar Smart Energy Hub, aimed at providing reliable power solutions for winter outages and off-grid adventures [1][2]. Product Overview - The Elite 400 Portable Power Station features a battery capacity of 3,840Wh and a rated output of 2,600W, with a lifting power of 3,900W, suitable for running essential home appliances during outages [3]. - The Elite 400 is designed for mobility with integrated rolling wheels and a telescopic handle, making it easy to transport [4]. - The Elite 400 includes smart power control features via the BLUETTI App, allowing for functionalities like Sleep Mode and Remote Wakeup, and can recharge to 80% in 70 minutes using AC and solar dual fast charging [5]. Charger 2 Features - The Charger 2 combines vehicle alternator charging and solar input, allowing both power sources to operate simultaneously for a total charging power of up to 1,200W, significantly faster than standard 12V outlets [6][7]. - It is compatible with 95% of third-party portable power stations and can act as the central management system for vehicle energy, intelligently switching between power sources [8]. - The Charger 2 includes advanced features for vehicle battery maintenance, such as emergency jumpstart and app-based monitoring via Bluetooth and Wi-Fi [9]. Pricing and Availability - Both products are available for purchase starting January 6, 2026, with Early Bird pricing: Elite 400 at $1,899 and Charger 2 at $499, along with additional discounts for early buyers [10][11].

Company Overview - Soren Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, focusing on the healthcare industry [2]. Initial Public Offering (IPO) Details - The company announced the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit, with trading expected to begin on January 7, 2026, under the ticker symbol "SORNU" [1]. - Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant allowing the purchase of one Class A ordinary share at a price of $11.50 per share [1]. - The offering is expected to close on January 8, 2026, subject to customary closing conditions, and underwriters have a 45-day option to purchase an additional 3,300,000 units to cover over-allotments [1]. Management Team - The management team is led by Arghavan Di Rezze (CEO) and Jamie Weber (CFO), both of whom are members of the Board of Directors, which also includes Marc Mazur, Charles N. Khan III, and Spencer Gerrol [3]. Underwriters and Legal Counsel - BTIG, LLC is acting as the sole book-running manager for the offering, while Reed Smith LLP and Walkers (Cayman) LLP serve as legal counsel to the company [4].

Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

Core Insights - Faraday Future will host its Stockholders' Day on January 7, 2026, during CES, focusing on transparency, execution updates, and long-term value creation [1][6] - The event will be livestreamed globally, allowing stockholders and others to participate in real-time [1][4] Event Details - Date: January 7, 2026 - Check-in Time: 3:30 PM – 4:00 PM PST - Program and Q&A: 4:00 PM – 5:00 PM PST - Location: Renaissance Las Vegas Hotel, 3400 Paradise Rd, Las Vegas, NV 89169 [3][4] Program Highlights - The event will provide updates on the Company's progress, priorities, and next phase of execution, including: - Full FX Super One vehicle roadmap announcement covering mass production, sales, delivery, service, and ramp-up plan [5] - Upgrade of the Bridge Strategy from the Global Automotive Industry Bridge Strategy to the Global EAI Industry Bridge Strategy [5] - Private preview of new product categories [5] Company Overview - Faraday Future is a California-based global shared intelligent electric mobility ecosystem company, founded in 2014, aiming to disrupt the automotive industry with a user-centric, technology-first approach [7] - The flagship model, FF91, represents the vision for luxury, innovation, and performance, while the new FX brand strategy targets a broader market with middle-to-low price range offerings [7]

Core Viewpoint - Galantas Gold Corporation has entered into a share purchase agreement to acquire a 100% ownership interest in the Andacollo Oro Gold Project in Chile, marking a significant strategic move for the company and expected to be classified as a Fundamental Acquisition under TSX Venture Exchange policies [1] Project Overview - The Andacollo Oro Gold Project is located in the Coquimbo Region of Chile, approximately 55 kilometers southeast of La Serena, at an elevation of 1,100 meters, featuring a substantial permitted footprint with mining concessions, land title, and water rights [2] - The project includes existing infrastructure, extensive earthworks, and three leach pads, providing excellent access to services and a skilled workforce [2] Historical Resource Estimates - The historical mineral resource estimate indicates measured and indicated resources of 2.02 million ounces of gold from 130 million tonnes at a grade of 0.48 grams per tonne, with inferred resources of 5.06 million ounces from 358 million tonnes at a grade of 0.45 grams per tonne [3] - The project has a historical production record of 1.12 million ounces of gold from 1998 to 2018, with peak annual production of approximately 135,000 ounces [4] Geological and Technical Aspects - The project features a low-sulphidation epithermal, manto-style gold system, supported by a robust technical database from 1,600 drill holes totaling approximately 190,000 meters [5] - The project is adjacent to the Carmen del Andacollo porphyry copper mine, which produces about 45,000 tonnes of copper per year [6] Strategic Importance - The acquisition is seen as a transformative step for Galantas, enhancing its profile and scale by adding a large-scale, past-producing gold asset with existing infrastructure and a deep technical database [7] - The project offers multiple development pathways and significant exploration potential for additional gold and copper mineralization [8] Transaction Structure - The total cash consideration for the acquisition is structured at US$32 million, with staged payments over four years, reflecting a commitment to capital discipline [12] - The transaction includes the issuance of 91,313,890 common shares to the controlling shareholder of Dragones, representing 19.9% of Galantas' outstanding shares, subject to approvals [12][13] Financial Overview - As of December 31, 2025, Sol, the entity acquiring the project, reported total assets of approximately US$4.28 million and total liabilities of approximately US$4.34 million, resulting in a loss of US$67,521 [10] Exploration Opportunities - The project has significant exploration upside, with potential for grade enhancement through angle-drilling and opportunities to increase resources along strike and down-dip of known mineralization [25] - There are indications of high-grade copper targets and numerous unexplored gold-copper occurrences on the project [26] Conditions to Closing - The completion of the transaction is subject to board approval, regulatory requirements, and shareholder approvals, including minority approval requirements [31][28]

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline.Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, com ...

Core Insights - Evergreen Marine has upgraded its fleet to Inmarsat's NexusWave bonded connectivity solution, enhancing crew experience and accelerating digitalisation [1][2][3] Group 1: Company Developments - Evergreen Marine is the first Taiwanese operator to implement the NexusWave solution, reinforcing its long-standing partnership with Inmarsat Maritime [1] - The upgrade to NexusWave introduces bonded, multi-network connectivity, providing fast speed, unlimited data, and always-on performance for crew and operations [2] - The solution is designed to enhance crew welfare, strengthen cybersecurity, and support operational excellence [3] Group 2: Technological Advancements - NexusWave leverages the ViaSat-3 ultra-high-capacity network, enabling scalable platforms for predictive analytics and real-time monitoring across the fleet [2] - The solution is secure-by-design and engineered to scale with demand, aligning with Evergreen's growth plans [2][3] - The transition to NexusWave is part of Evergreen's 'Evergreen IT' modernisation programme, aimed at continuous innovation for customers [1][3]

The UAV-P300 is an AI-powered enterprise drone platform built for clear imaging in fog, reliable day-night operations, and safe autonomous flight across complex environments LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- -- CES -- GDU, a professional-grade drone leader established in 2015, today announced the launch of UAV-P300, the world’s first AI-powered optical and electronic fog-penetrating drone. Purpose-built for public safety, smart city operations, aerial surveying, and cultural tourism, the UAV-P300 ...